Exocell 特约代理

Exocell—糖尿病研究相关产品

Exocell公司是一家专注于糖尿病及其并发症研究相关的产品与服务美国高科技生物制品公司,该公司提供的糖尿病研究产品,涵盖临床诊断、临床研究及基础实验研究领域,包括人、小鼠、 大鼠尿蛋白和糖基化蛋白,人纤连蛋白、载脂蛋白B等一系列试剂盒和抗体,其高品质的产品欧美。作为开发,营销和执行新的临床诊断化验者,Exocell公司已经并且正在为糖尿病及其相关的肾脏和血管疾病领域的基础科研、实验动物研究以及临床诊断和治疗研究提供的产品和研发服务。

Exocell公司的主要产品:

一、临床诊断检测对于糖尿病及其并发症的治疗和管理至关重要,在该领域中Exocell公司提供的临床诊断相关产品包括:

Albuwell用于检测微白蛋白尿,是早期糖尿病性肾功能紊乱的明确标志物。

Creatinine用于检测尿中的creatinine.

Glycaben用于监测糖化白蛋白(中期的控糖指标)

Glycacor用于检测糖化LDL(短期控糖指标及心血管疾病风险指标)

Hemoglobin A1c参照标准(长期控糖指标)

 

二、临床研发类检测试剂与试剂盒测定大量人类糖尿病及其并发症的重要指标,在该领域中Exocell公司提供的相关产品包括:

Apo B Test用于检测人血浆中的apolipoprotein B

Collagen IV H用于检测 样本中的IV 型胶原

hFibronectin ELISA试剂盒用于检测人血浆中的fibronectin

Nephrin ELISA试剂盒用于检测尿液中的nephrin.

h-PODXL用于检测人组织或尿液样本中的podocalyxin

Beta-induced h3用于检测人尿液中的BIG-H3

Troponin – H用于检测人血浆或血清中的 Troponin I

TNF-sR2 用于检测人尿/血浆/血清中的TNF-α可溶性受体2

 

三、Exocell公司提供的糖尿病及其并发症的实验室研究相关产品,包括:

Albuwell M用于检测小鼠样本中的微白蛋白尿,

Nephrat II用于检测大鼠样本中的微白蛋白尿,

Albuwell C, O P 用于检测狗、绵羊及非人的灵长类动物样本中的微白蛋白尿,

Collagen IV M用于检测小鼠和大鼠样本中的IV型胶原,

Creatinine Companion用于检测人和啮齿类动物的creatinine.

Glyco-Albumin R用于检测大鼠血清中的糖化白蛋白,

Nephrin ELISA to measure rodent urinary nephrin.

CRP ELISA试剂盒用于检测啮齿类动物血浆中的C-reactive蛋白.

Adiponectin ELISA试剂盒用于检测人尿和血浆中的adiponectin

Beta-induced h3用于检测人尿中的BIG-H3

Troponin M用于检测小鼠血浆/血清中的Troponin I

Troponin R用于检测大鼠血浆/血清中的Troponin I

PODXL–R用于检测啮齿类动物尿液中的podpcalyxin

 

四、糖尿病及其并发症研究相关的试剂及标准参照品,包括高特异性的单克隆抗体及高度纯化的蛋白,,在该领域中Exocell公司提供的相关产品包括:

A717:抗糖化白蛋白单克隆抗体

E85: 抗糖化血红素的单克隆抗体

ES12:抗糖化LDL的单克隆抗体

糖化血红素片段(gly Hb, HbA1c, glyHbA0, HbA1a, b)

去糖的血红素片段(degly Hb, degly HbA0)

糖化的白蛋白(NGA/SGA)

去糖化的白蛋白

 

部分使用Exocell公司产品的相关文献:

  1Albuwell M

  • American Journal Physiology Renal Physiology 293:F1657-1665, 2007
    Interference with TGF-B signalling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria
  • American Journal Physiology Renal Physiology 292:F321-329, 2007
    Soluble betaglycan reduces renal damage progression in db/db mice
  • Nephron Experimental Nephrology 105:e45-e52, 2007
    Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice
  • American Journal Physiology Renal Physiology 290:F214-F222, 2006
    Impact of genetic background on nephropathy in diabetic mice
  • American Journal Physiology Heart Circ Physiology 290:H935-H940, 2006
    Angiotensin II hypertension is attenuated in interleukin-6 knockout mice
  • American Journal Physiology Renal Physiology 291:F1315-F1322, 2006
    Characterization of diabetic nephropathy in a transgenic model of hypoinsulinemic diabetes
  • American Journal Physiology Renal Physiology 290:F813-820, 2006
    SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice
  • American Journal Physiology Renal Physiology 290:F828-F837, 2006
    Adenosine A2a receptor activation attenuates inflammation and injury in diabetic nephropathy
  • Nephron Experimental Nephrology 104:e23-e34, 2006
    Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice
  • Journal American Society Nephrology 16:27-45, 2005
    Mouse models of diabetic nephropathy
  • American Society Nephrology 16:1289-1299, 2005
    Genome-wide scan in a novel IgA nephropathy model identifies a susceptibility locus on murine chromosome 10, in a region syntenic to human IGAN1 on chromosome 6q22-23
  • Diabetes 54:2628-2637, 2005
    Characterization of susceptibility of inbred mouse strains to diabetic nephropathy
  • American Journal Pathology 165:1243-1255, 2004
    Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules
  • Hypertension 43:364-369, 2004
    Role for thromboxanes receptors in angiotensin-II-induced hypertension
  • Journal Clinical Investigation 113:1390-1397, 2004
    Induction of B7-1 in podocytes is associated with nephritic syndrome
  • Diabetes 53:2101-2109, 2004
    Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-?-deficient mice
  • Journal American Society Nephrology 14:1200-1211, 2003
    Focal and segmental glomerulosclerosis in mice with podocyte-specific expression of mutant ?-actinin-4
  • American Journal Pathology 162:1123-1137, 2003
    RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy
  • Kidney International 64:1978-1985, 2003
    Gene expression profile in diabetic KK/Ta mice
  • Journal of Immunology 170:5658-5666, 2003
    CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration

      2Glycacor

  • Atherosclerosis 202:162-168, 2009
    Glycation of LDL in non-diabetic people: Small dense LDL is preferentially glycated both in vivo and in vitro
  • Immunopharmacology Immunotoxicology 15:1-12, 2008
    Evaluation of serum biomarkers in nutritional disorders: Glycated apolipoprotein B, fasting serum glucose, fructosamine, stable and labile glycated hemoglobin in diabetic and non-diabetic subjects
  • Nutrition Metabolism & Cardiovascular Disease 17:6-12, 2007
    Glycated apolipoprotein B and myocardial infarction
  • Circulation 109:1750-1755, 2004
    Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes
  • Diabetes Technology & Therapeutics 6:348-356, 2004
    Increased plasma glycated low-density lipoprotein concentrations in diabetes: A marker of atherogenic risk
  • Journal American Society Nephrology 10:332-341, 1999
    Non-insulin dependent diabetes mellitus and hypertriglyceridemia impair lipoprotein metabolism in chronic hemodialysis patients
  • Nephrology Dialysis Transplantation 12:1336-1343, 1997
    Uptake and metabolism of lipoproteins from patients with diabetes mellitus type II by glomerular epithelial cells

3Nephrat

  • Cell Biochemistry Biophysics 48:147-157, 2007
    Novel inhibitors of glycation and AGE formation
  • American Journal Physiology Regul Integr Comp Physiology 292:R769-R777, 2007
    17-estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney
  • Diabetes 56:1842-1849, 2007
    Hyperglycemia is a major determinant of albumin permeability in diabetic microcirculation
  • American Journal Physiology Renal Physiology 290:F828-F837, 2006
    Adenosine A2a receptor activation attenuates inflammation and injury in diabetic nephropathy
  • Laboratory Investigation 86:357-368, 2006
    Expression of Smad1 is directly associated with mesangial matrix expansion in rat diabetic nephropathy
  • FASEB Journal 20:E150-E159, 2006
    Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers
  • American Journal Physiology Regul Integr Comp Physiology 290:R435-R441, 2006
    Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes
  • Laboratory Investigation 86:927-939, 2006
    Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy
  • American Journal Physiology Renal Physiology 289:F442-450, 2005
    Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone
  • Diabetologia 46:1140-1152, 2003
    LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats
  • Journal American Society Nephrology 14:709-720, 2003
    Delayed treatment with lithospermate B attenuates experimental diabetic renal injury
  • Journal American Society Nephrology 14:3178-3187, 2003
    Role of 12-lipoxygenase in the stimulation of p38 mitogen-activated protein kinase and collagen ?5(IV) in experimental diabetic nephropathy and ion glucose-stimulated podocytes
  • American Journal Pathology 158:1733-1741, 2001
    A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis
  • American Journal Society Nephrology 12:993-1000, 2001
    Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes

      4Collagen Type IV

  • Diabetologia 51:198-207, 2008
    Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells
  • Nephron Experimental Nephrology 105:e45-e52, 2007
    Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice
  • American Journal Physiology Renal Physiol 292:F789-F795, 2007
    Inhibiting albumin glycation attenuates dysregulation of VEGFR-1 and collagen IV subchain production and the development of renal insufficiency
  • American Journal Physiology Renal Physiology 290:F813-820, 2006
    SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice
  • Kidney International 68:1554-1561, 2005
    Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy
  • Kidney International 64:1632-1642, 2003
    Vitamin D3 up-regulated protein-1 regulates collagen expression in mesangial cells
  • Metabolism 50:1435-1440, 2001
    Increased urinary type IV collagen marks the development of glomerular [athology in diabetic db/db mice
  • Diabetes Care 24:914-918, 2001
    Increased collagen IV excretion in diabetes
  • Diabetes Care 24:1324-1327, 2001
    Serum type IV collagen in diabetic patients at risk for nephropathy

5Nephrin

  • PLoS One 7(5):e36041, 2012
    Dysregulated nephrin in diabetic nephropathy of type 2 diabetes: A cross sectional study
  • Am J Physiol Renal Physiol 302:F1084-F1089, 2012
    Increased urinary excretion of nephrin, podocalyxin and ?ig-h3 in women with preeclampsia

6Podocalyxin

  • Am J Physiol Renal Physiol 302:F1084-F1089, 2012
    Increased urinary excretion of nephrin, podocalyxin and βig-h3 in women with preeclampsia

7 βig-h3

  • Am J Physiol Renal Physiol 302:F1084-F1089, 2012
    Increased urinary excretion of nephrin, podocalyxin and βig-h3 in women with preeclampsia